SMI-4a
CAS No. 327033-36-3
SMI-4a ( SMI-4a )
Catalog No. M18425 CAS No. 327033-36-3
TCS-PIM-1-4a, a Pim inhibitor, blocks mTORC1 activity through activation of AMPK and kills a wide range of both myeloid and lymphoid cell lines (IC50=0.8-40 μM).
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 42 | In Stock |
|
10MG | 63 | In Stock |
|
25MG | 113 | In Stock |
|
50MG | 203 | In Stock |
|
100MG | 305 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSMI-4a
-
NoteResearch use only, not for human use.
-
Brief DescriptionTCS-PIM-1-4a, a Pim inhibitor, blocks mTORC1 activity through activation of AMPK and kills a wide range of both myeloid and lymphoid cell lines (IC50=0.8-40 μM).
-
DescriptionTCS-PIM-1-4a, a Pim inhibitor, blocks mTORC1 activity through activation of AMPK and kills a wide range of both myeloid and lymphoid cell lines (IC50=0.8-40 μM).
-
SynonymsSMI-4a
-
PathwayMAPK/ERK Signaling
-
TargetERK
-
RecptorPim 1; Pim 2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number327033-36-3
-
Formula Weight273.23
-
Molecular FormulaC11H6F3NO2S
-
Purity98%
-
SolubilityDMSO : ≥ 100 mg/mL; 365.99 mM
-
SMILESc1cc(cc(c1)C(F)(F)F)/C=C/1\C(=O)NC(=O)S1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lin YW, et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood. 2010 ;115(4):824-33.
molnova catalog
related products
-
Isomeranzin
Isomeranzin has anti-inflammatory activity, it suppresses inflammation by inhibiting M1 macrophage polarization through the p65, NF-κB and ERK pathway.
-
CAFESTOL
CAFESTOL is a ERK inhibitor for AP-1-targeted activity against PGE2 production and the mRNA expression of cyclooxygenase (COX)-2 in LPS-activated RAW264.7 cells.?Cafestol has strong inhibitory activity on PGE2 production by suppressing the NF-kB activation pathway.
-
Byakangelicol
Byakangelicol may inhibit P-gp expressed at the BBB even under in vivo conditions.